Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03341936
Title Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

nasopharynx carcinoma

head and neck squamous cell carcinoma

oral squamous cell carcinoma

hypopharynx cancer

Therapies

Lirilumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.